A sweeping update to the European Medicines Agency's regulatory framework for peptide-based therapeutics, finalized in May 2026 after three years of stakeholder consultation, is creating unexpected compliance pressures for American peptide businesses that source from European suppliers, operate partnership arrangements with EU-based manufacturers, or export finished products into European markets.
The EMA's Peptide Therapeutics Regulatory Harmonization Directive, adopted by the European Commission on May 15 and effective immediately for new product applications, establishes a unified set of quality standards, nomenclature requirements, and post-market surveillance obligations across all 27 EU member states. While the directive is nominally an internal European matter, its provisions carry significant implications for the cross-border peptide industry precisely because of how deeply intertwined European and American supply chains have become.
"A lot of U.S. compounders don't realize how much of their supply chain has European fingerprints on it," said Dr. Lieselotte van der Berg, a pharmaceutical regulatory advisor based in Amsterdam who has consulted for U.S.-facing peptide companies. "When the EMA moves, American companies feel it, whether or not they've ever filed a European application."
What the Directive Changes
The harmonization directive makes six categories of regulatory changes that have direct or indirect relevance for U.S. peptide businesses:
Nomenclature standardization. The EMA has adopted a unified International Nonproprietary Name framework for peptide therapeutics that replaces the inconsistent naming conventions that existed across member states. For U.S. companies working with European partners or seeking European market access, documentation using outdated nomenclature will now be returned for correction.
Bioequivalence standards for compounded peptides. The directive establishes the first EU-wide bioequivalence standards specifically applicable to compounded peptide formulations. While these standards primarily govern EU compounders, U.S. facilities exporting to EU markets, including several 503B outsourcing facilities that have developed export business, must now meet these standards to maintain access.
Post-market surveillance reporting timelines. The directive tightens adverse event reporting timelines from 30 days to 15 days for serious adverse events involving peptide therapeutics. U.S. manufacturers and exporters participating in EU clinical programs must update their pharmacovigilance workflows accordingly.
Certificate of Analysis mutual recognition. The EMA has established a mutual recognition framework for CoA documentation with a limited set of non-EU trading partners. The United States is not currently included in this framework, which means that U.S.-sourced APIs used in EU-compounded products must still undergo full independent testing rather than relying on U.S.-generated quality documentation.
Good Manufacturing Practice equivalency assessment. The directive requires the EMA to assess the GMP frameworks of major non-EU supplier countries by December 2026. A negative assessment for any country, including the United States, could trigger additional testing and documentation requirements for products from that country entering the EU market.
Stability testing protocol updates. New long-term stability testing requirements for injectable peptide formulations extend the required study duration and add new environmental stress conditions. U.S. companies seeking EU market access for compounded or manufactured peptide products must generate data under the updated protocols.
The Supply Chain Exposure
For U.S. peptide businesses, the directive creates compliance exposure across three primary channels:
European API sourcing. Several U.S. compounders source peptide APIs from European manufacturers, particularly from Switzerland, Germany, and the Netherlands, where a number of high-quality peptide synthesis operations are headquartered. The directive's new quality documentation requirements mean that these suppliers will need to update their CoA formats and testing protocols, which may temporarily disrupt supply and will likely increase per-unit costs as suppliers absorb compliance investments.
Technology licensing arrangements. Some U.S. peptide manufacturers have entered into technology licensing arrangements with European pharmaceutical companies for proprietary peptide formulation technologies. These arrangements typically include quality system requirements tied to the licensor's regulatory framework. As the licensor's framework changes under the new EMA directive, U.S. licensees may find that their quality systems require updating to remain compliant with licensing terms.
Parallel export channels. A growing number of U.S. compounding pharmacies have developed export capabilities, supplying compounded peptide products to patients in countries that permit such imports. The EU member states represent a significant portion of this export market. The directive effectively raises the bar for what these exports must demonstrate in terms of quality and documentation.
Practical Compliance Steps for U.S. Companies
For U.S. businesses with European supply chain exposure, regulatory advisors recommend a structured impact assessment as the immediate priority:
Map your EU touchpoints. Identify every point in your supply chain where a European entity plays a role, whether as API supplier, technology licensor, contract research organization, or distribution partner. Each touchpoint represents a potential compliance impact from the new directive.
Review your European partner agreements. Supply and licensing agreements that reference EMA regulatory standards will likely require updates or at minimum confirmation that the European party's updated compliance posture satisfies existing contractual quality requirements.
Assess CoA documentation against new format requirements. If you source APIs from EU-based manufacturers, request documentation of how their CoA format is changing under the directive and evaluate whether your internal quality systems need updating to process the new format.
Engage European regulatory counsel early. The directive is complex and its implications for specific business arrangements require expert analysis. U.S. companies with significant European exposure should not rely solely on domestic regulatory counsel for this assessment.
For companies in the process of building out their regulatory affairs function, the peptide regulatory affairs VA role provides a scalable resource for monitoring and responding to international regulatory developments of this kind.
The FDA-EMA Relationship Dimension
The expanded EMA directive comes at a moment when FDA-EMA regulatory cooperation is being discussed at a policy level. Both agencies have publicly expressed interest in greater transatlantic harmonization of pharmaceutical regulatory frameworks, and a formal memorandum of understanding on pharmaceutical regulation has been under discussion since early 2025.
If FDA-EMA harmonization advances, the EMA's new peptide framework could serve as a template for updated FDA guidance, meaning that the European standards being implemented today may well become U.S. requirements in two to four years. For forward-thinking U.S. companies, building EMA-compliant systems now could provide a competitive advantage when domestic harmonization occurs.
"The direction of travel in pharmaceutical regulation globally is harmonization," said van der Berg. "Companies that invest in systems flexible enough to meet multiple regulatory frameworks are going to be much better positioned than companies that optimize narrowly for one jurisdiction."
Market Implications
The directive is expected to have several market-level effects on the global peptide industry over the next 18 months. European peptide compounders that are already compliant with the new standards may gain a competitive advantage over smaller domestic operators still catching up. U.S. exporters that cannot quickly meet the new requirements may find their European market access narrowed until compliance is achieved.
From a staffing perspective, the increased complexity of international regulatory compliance is driving demand for professionals with cross-jurisdictional pharmaceutical regulatory expertise. Peptide businesses that anticipate needing European regulatory capabilities should be evaluating their talent requirements now, before the market for that expertise tightens further.
The directive represents the latest in a series of regulatory developments, across both the U.S. and Europe, that are collectively reshaping the compliance landscape for the global peptide industry. Businesses that have treated regulatory affairs as a back-office function are increasingly finding that it needs to be a front-of-house strategic priority.
Topics
PeptideStaff Editorial Team
Healthcare Staffing Specialists
Collective expertise across clinical staffing, regulatory compliance, and peptide industry operations
Our editorial team combines backgrounds in healthcare recruitment, peptide research, and clinical operations to produce accurate, actionable staffing and industry guidance for peptide businesses.
Reviewed by the PeptideStaff Editorial Team, April 2026